Bicara Therapeutics Inc.
BCAX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002023658
In the last 90 days, Bicara Therapeutics Inc. insiders filed 0 open-market purchases and 1 sale; 172 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $665.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $400.7K in total
- 1
- 13F holdersQ2 2026, +28 vs. previous quarter
- 172
- 13F valueReported value at the end of Q2 2026
- $2.07B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$137.9M
- No comparable prior period
- Free cash flow, FY2025
- -$107.1M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 9.86M
- Shares sold short
- Change
- −436.4K
- −4.2% vs. previous
- Days to cover
- 3.84
- At average daily volume
Superinvestors holding BCAX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding BCAX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Bicara Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)4:23 PM ET | Sep 8 | 2 days | Cohlhepp RyanPresident, COO & Interim CEO | SSale | −17.5K | $22.90 | −$400.7K | −8.8%181.6K after | 2 lots10b5-1 |
| Aug 12, 2026 (view filing)4:19 PM ET | Aug 10 | 2 days | Hyep IvanChief Financial Officer | SSale | −12.5K | $27.97 | −$349.6K | −8.8%129.9K after | 10b5-1 |
| Aug 12, 2026 (view filing)4:19 PM ET | Aug 10 | 2 days | Mazumdar ClaireChief Executive Officer | SSale | −10.0K | $27.98 | −$279.8K | −2.7%362.2K after | 10b5-1 |
| Aug 12, 2026 (view filing)4:19 PM ET | Aug 10 | 2 days | Cohlhepp RyanPresident and COO | SSale | −18.8K | $27.98 | −$524.5K | −9.4%181.6K after | 10b5-1 |
| Jul 14, 2026 (view filing)4:22 PM ET | Jul 10 | 4 days | Mazumdar ClaireChief Executive Officer | SSale | −10.0K | $28.42 | −$284.2K | −2.7%362.2K after | 2 lots10b5-1 |
| Jul 10, 2026 (view filing)4:10 PM ET | Jul 8-9 | 2 days | Cohlhepp RyanPresident and COO | SSale | −28.8K | $28.98 | −$833.1K | −13.7%181.6K after | 4 lots10b5-1 |
| Jul 10, 2026 (view filing)4:10 PM ET | Jul 8 | 2 days | Hyep IvanChief Financial Officer | SSale | −28.0K | $28.85 | −$807.7K | −17.7%129.9K after | 3 lots10b5-1 |
| May 26, 2026 (view filing) | May 21 | 5 days | Hyep IvanChief Financial Officer | SSale | −9.20K | $20.42 | −$187.9K | −6.0%145.4K after | 10b5-1 |
| May 20, 2026 (view filing) | May 18 | 2 days | Mazumdar ClaireChief Executive Officer | SSale | −15.0K | $20.04 | −$300.6K | −4.0%362.2K after | 2 lots10b5-1 |
| May 18, 2026 (view filing) | May 15 | 3 days | Cohlhepp RyanPresident and COO | SSale | −12.5K | $20.29 | −$253.6K | −6.1%191.6K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 172 holdersThe largest institutional positions in Bicara Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 7,255,993 | $215.4M | 1.87% | 00.0% | Unchanged |
| T. Rowe Price Investment Management, Inc. | 6,338,487 | $188.2M | 0.12% | −267,293−4.0% | Reduced |
| Siren, L.L.C. | 5,602,970 | $166.4M | 3.38% | −200,000−3.4% | Reduced |
| Vestal Point Capital, LP | 5,250,000 | $155.9M | 3.64% | −175,000−3.2% | Reduced |
| Deep Track Capital, LP | 4,100,000 | $121.7M | 1.79% | +37,500+0.9% | Added |
| BlackRock, Inc. | 3,848,090 | $114.2M | 0.00% | +1,004,383+35.3% | Added |
| Jupiter Topco LLC | 3,171,015 | $94.0M | 0.04% | +3,171,015 | New |
| Red Tree Management, LLC | 3,163,517 | $93.9M | 63.77% | −6,992−0.2% | Reduced |
| TPG GP A, LLC | 3,010,425 | $89.4M | 1.79% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,216,639 | $65.8M | 0.00% | +442,419+24.9% | Added |
Holders of 5% or more of BCAX
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Bicara Therapeutics Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 11.50%7.28M shares | – | Sep 23, 20242 filings | Mar 2, 2026 | SEC |
| Invus Global Management, LLC | 13G/A | 9.60%5.22M shares | – | Sep 26, 20242 filings | Jul 31, 2025 | SEC |
| Vestal Point Capital, LP | 13G/A | 8.30%5.42M shares | +1.80 ppfrom 6.50% | May 15, 20254 filings | May 15, 2026 | SEC |
| Deep Track Capital, LP | 13G/A | 6.21%4.06M shares | +1.19 ppfrom 5.02% | Feb 12, 20262 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.40%3.54M shares | New | Jul 27, 20261 filing | Jul 27, 2026 | SEC |